Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
DGX · NYSE · Healthcare
Fundamental quality
59
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $10,788M | $1,995M | $1,830M | $3,140M |
| 2022 | $9,883M | $946M | $1,314M | $3,665M |
| 2023 | $9,252M | $854M | $864M | $4,027M |
| 2024 | $9,872M | $871M | $909M | $5,668M |
| 2025 | $11,035M | $992M | $1,359M | $5,251M |
Between 2021 and 2025, revenue went from $10,788M to $11,035M (+2%) and net income went from $1,995M to $992M (-50%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Quest Diagnostics Inc a profitable company?
Quest Diagnostics Inc is profitable, with a net margin of 9.1%, though a thin one.
Does Quest Diagnostics Inc have a lot of debt?
A moderate level: its net debt is 2.41 times its EBITDA.
Is Quest Diagnostics Inc growing?
Its revenue has grown 4.2% annualized in recent years and its earnings per share 4%.
Does Quest Diagnostics Inc generate cash?
Yes. It converts about 11.8% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Quest Diagnostics Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →